Longevity World Forum is the new international meeting in Valencia that will promote knowledge on human longevity
An opportunity for the scientific community to share and develop advances in human longevity. This is the aim of Longevity World Forum, a new global meeting, which is the first of its kind in Europe and will take place on the 7th and 8th of November in Valencia gathering eminent personalities in the field of human longevity both from Spain and abroad.
Among others, the following renowned professionals will take part in Longevity World Forum: Aubrey de Grey, biomedical gerontologist at SENS Research Foundation; Christoph Lippert, data science specialist at Human Longevity; María Blasco Marhuenda, head of the Spanish National Cancer Research Centre; Manuel Corpas, CEO and founder of Cambridge Precision Medicine; and Santiago Grisolía, biochemist, Prince of Asturias Award winner and chairman of the Scientific Committee of the Human Genome Project for UNESCO.
Longevity World Forum aims at becoming a meeting point for scientists and other international actors involved in research and the development of approaches for increased life expectancy and improved life quality. The world forum will last two days and its programme will address fields such as genomics, biotechnology and nutrition applied to human longevity, which is a matter people are growing increasingly concerned about.
This exchange of ideas and synergies will take place at Hotel Las Arenas Balneario Resort next autumn. The hotel is located in Valencia, the city chosen to host the first edition of Longevity World Forum and to be the permanent venue of the event. Longevity World Forum is a project organized by the consulting firm Talentum Group in collaboration with the journal Genética Médica News and the company Cambridge Precision Medicine.
The tickets for the first edition of Longevity World Forum are limited and available on the official website: www.longevityworldforum.com.
Doctor in Pharmacy and President of Eugenomic
Born in 1934, he began to research in the field of genetic diseases and preventive medicine from the beginning of his career. He was professor of Biochemistry at the Faculty of Medicine of the UAB and director of the Institute of Clinical Biochemistry – a center specialized in the study of congenital metabolic diseases – for fifteen years. He is the honorary president of the Royal Academy of Pharmacy of Catalonia and member of the Royal Academy of Medicine of Catalonia too. Besides, he is founder and president of Eugenomic, a corporation specialized in genomic medicine that has created the g-Nomic® Pharmacogenetics software for a fully customized prescription. Juan Sabater has received many awards, such as the Cross of Health, the Encomienda of Alfonso X ‘the Wise’ and the Creu de Sant Jordi.
Department of Physiology, Freshage Research Group, University of Valencia, CIBERFES, INCLIVA, Valencia, Spain
Born in 1953, José Viña is Professor of Physiology at the University of Valencia. He obtained his PhD at Valencia University in 1976 and has honoris causa doctorates from the University of Rennes (France) and the University of Buenos Aires (Argentina). Once he had finished his degree in Medicine at the University of Valencia in 1974, José Viña started biomedical investigation at the Medical Research Council of the University of Oxford, which at that time was run by the Nobel Laureate, Hans Krebs. Subsequently, he worked as professor of Physiology at the University of Extremadura. In 1984, he was designated professor at the Department of Physiology of the University of Valencia. He has published over 330 international papers and has received several honours, including the Albert Struyvenberg medal awarded by the European Society for Clinical Investigation (ESCI) 2017, for leadership in research in ageing and exercise. He is also the author of the book “Cuídese hoy para que no le cuidemos mañana: cómo vivir para envejecer mejor” (2009). José Viña specialises in nutrition and exercise and their application in healthy ageing. He has been leading a successful research group dealing with nutritional aspects, with longevity and, more recently, with frailty and Alzheimer’s disease.